Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Avexa has announced encouraging 48 week data from the apricitabine's Phase IIb clinical trial.
Subscribe to our email newsletter
At week 48 the proportion of patients with HIV levels below detectable was over 90%. Patients who were initially treated with 3TC but who changed to apricitabine (ATC) at week 24 also improved their response after their switch to ATC.
Avexa also reported that the CD4 cell count of ATC treated patients continued to increase out to 48 weeks. Patients initially treated with 3TC and then switched to ATC doubled their levels of CD4 cell count at week 48 (after 24 weeks of ATC) compared to their CD4 cell count after 24 weeks of 3TC.
No ATC resistance has been identified after 48 weeks of therapy. This demonstrated ability of ATC to withstand selection of HIV resistance, even in patients who have already failed other drugs, and differentiates it from some of the other HIV drugs in clinical use.
Julian Chick, CEO of Avexa, said: “These 48 week results clearly define ATC as a drug with huge potential both for drug-resistant patients in need of potent and safe new HIV therapies and for patients whose regimen currently contains 3TC.”